FibroBiologics announced the development of a novel artificial thymus organoid that can restore immune function in a severe combined immunodeficiency mouse model. The organoid, composed of fibroblasts and thymus derived cells, is capable of generating mature and diverse T cells, including CD4, CD8, and regulatory T cells, in vitro and in vivo. FibroBiologics intends to develop this technology as a subcutaneous injection of an allogeneic fibroblast-based organoid to restore thymus function lost due to age-related natural thymus involution, and for a rapid restoration of the immune system in patients who have gone through chemotherapy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBLG:
- FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology
- Fibrobiologics Inc trading resumes
- Fibrobiologics Inc trading halted, volatility trading pause
- FibroBiologics files to sell 16.02M shares of common stock for holders
- FibroBiologics Set to Join Russell 2000® Index